Thus, the purpose of the current study was to investigate and characterize the structural subsets of TP53 mutations, and to evaluate these data in the context of the MIR34 family- and DAPK promoter methylation status to the clinical outcome in a large cohort of patients with PCNSL of the DLBCL subtype. Here, TP53 is linked to diffuse large B-cell lymphoma.